Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1441-1447

  Langhans, Bettina ^a   Braunschweiger, Ingrid ^a   Schweitzer, Susann ^a   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

ELISPOT technique; HCV derived lipopeptide; Primary B cell response; SFC; Spot forming cells

Indexed keywords

ARGINYLARGINYLGLYCYLPROLYLARGINYLLEUCYLGLYCYLVALYLARGINYLALANYLTHREONYLARGI NYLLYSYLTHREONYLSERYLGLUTAMYLARGINYLSERYLGLUTAMINYLPROLYLARGINYLGLYCYLARGINYLARG INYLGLUTAMINE; ASPARAGINYLLEUCYLGLYCYLLYSYLVALYLISOLEUCYLASPARTYLTHREONYLLEUCYLTHREONYLCYS TEINYLGLYCYLPHENYLALANYLALANYLASPARTYLLEUCYLMETHIONYLGLYCYLTYROSYLISOLEUCYLPROLY LLEUCYLVALYLGLYCYLALANINE; CYSTEINYLGLYCYLPHENYLALANYLALANYLASPARTYLLEUCYLMETHIONYLGLYCYLTYROSYLISOLEU CYLPROLYLLEUCYLVALYLGLYCYLALANYLPROLYLLEUCYLGLYCYLGLYCYLALANYLALANYLARGINYLALANY LLEUCYLALANINE; EPITOPE; GLUTAMINYLASPARTYLVALYLLYSYLPHENYLALANYLPROLYLGLYCYLGLYCYLGLYCYLGLUTAMINYLI SOLEUCYLVALYLGLYCYLGLYCYLVALYLTYROSYLLEUCYLLEUCYLPROLYLARGINYLARGINYLGLYCYLPROLY LARGINYLLEUCINE; LIPOPEPTIDE; PEPTIDE DERIVATIVE; PROLYLGLYCYLTYROSYLPROLYLTRYPTOPHYLPROLYLLEUCYLTYROSYLGLYCYLASPARAGINYLGLUT AMYLGLYCYLCYSTEINYLGLYCYLTRYPTOPHYLALANYLGLYCYLTRYPTOPHYLLEUCYLLEUCYLSERYLPROLYL ARGINYLGLYCYLSERINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INCUBATION TIME; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS ANTIBODIES; HUMANS; LIPIDS; LYMPHOCYTE COUNT; MALE; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT; VIRAL CORE PROTEINS;

EID: 1842456944     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.014     Document Type: Article

References (35)

1. BenMohamed L., Wechsler S.L., Nesburn A.B. Lipopeptide vaccine - yesterday, today, and tomorrow. Lancet Infect. Dis. 2:2002;25-31.
2. ε-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J. Immunol. 164:2000;900-907.
3. Andrieu M., Desoutter J.-F., Loing E., Gaston J., Hanau D., Guillet J.G.et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J. Virol. 77:2003;1564-1570.
4. Aliprantis A.O., Yang R.-B., Mark M.R., Suggett S., Devaux B., Radolf J.D.et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 285:1999;736-739.
5. Düesberg U., Bussche vd A., Kirschning C.J., Miyake K., Sauerbruch T., Spengler U. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol. Lett. 89:2002;89-95.
6. Bessler W.G., Baier W., Esche vd U., Hoffmann P., Heinevetter L., Weismüller K.-H.et al. Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunisation. Behring Inst. Mitt. 98:1997;390-399.
7. Wiesmüller K.-H., Bessler W.G., Jung G. Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int. J. Peptide Protein Res. 40:1992;255-260.
8. Chin L.T., Hinkula J., Levi M., Ohlin M., Wahren B., Børrebaeck C.A.K. Site-directed primary in-vitro immunisation: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors. Immunology. 81:1994;428-434.
9. Hoffmann P., Loleit M., Mittenbühler K., Beck W., Weismüller K.-H., Jung G.et al. Induction of an epitope-specific humoral immune response by lipopeptide-hapten conjugates: enhancement of the anti-mellitin response by a synthetic T helper (TH)-cell epitope. FEMS Immunol. Med. Microbiol. 17:1979;225-234.
10. Zafiropoulos A., Andersson E., Krambovitis E., Børrebaeck C.A.K. Induction of antigen-specific isotype switching by in vitro immunisation of human naïve B lymphocytes. J. Immunol. Methods. 200:1997;181-190.
11. Di Bisceglie A.M., McHutchison J., Rice C.M. New therapeutic strategies for hepatitis C. Hepatology. 35:2002;224-231.
12. Seeff L.B., Zimmerman H.J., Wright E.C., Finkelstein J.D., Garcia-Pont P., Greenlee H.B.et al. A randomized, double blind controlled trail of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology. 72:1977;111-121.
13. Sanchez-Quijano A., Pineda J.A., Lissen E., Leal M., Diaz-Torres M.A., Garcia de Pesquera F.et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet. 1:1988;1245-1249.
14. Lechmann M., Ihlenfeldt H.G., Braunschweiger I., Giers G., Jung G., Matz B.et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology. 24:1996;790-795.
15. Børrebaeck C.A.K. Strategy for the production of human monoclonal antibodies using in vitro activated B cells. J. Immunol. Methods. 123:1989;157-165.
16. Langhans B., Lechmann M., Ihlenfeldt H.G., Jung G., Giers G., Schweitzer S.et al. A hepatitis C virus (HCV) core protein-derived peptide inhibits HCV-specific lymphocyte proliferation. Eur. J. Med. Res. 5:2000;115-120.
17. Schweitzer S., Schneiders A.M., Langhans B., Krass W., Jung G., Vidalin O.et al. Flow cytometric analysis of peptide binding to major histocompatibility complex class I for hepatitis C virus core T-cell epitopes. Cytometry. 41:2000;271-278.
18. Deres K., Schild H., Wiesmüller K.-H., Jung G., Rammensee H.-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 432:1989;561-564.
19. Ohlin M., Danielsson L., Carlsson R., Børrebaeck C.A.K. The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes. Immunology. 66:1989;485-490.
20. Sauzet J.-P., Déprez B., Martinon F., Guillet J.-G., Gras-Masse H., Gomard E. Long-lasting anti-viral cytotoxic T lymphocyte induced in vivo with chimeric-multirestricted lipopeptides. Vaccine. 13:1995;1339-1345.
21. Martinon F., Gras-Masse H., Boutillon C., Tartar A., Levy J.-P. Immunisation of mice with lipopeptides bypass the prerequisite for adjuvant: Immune response in BABL/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:1992;3416-3422.
22. Wiesmüller K.-H., Jung G., Hess G. Novel low-molecular-weight synthetic vaccine against foot- and mouth disease containing a potent B-cell and macrophage activator. Vaccine. 7:1989;29-33.
23. Vitiello A., Ishioka G., Grey H.M., Induction of a primary cytotoxic T lymphocyte response in humans I. J. Clin. Invest. 95:1995;341-349.
24. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K.et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162:1999;3088-3095.
25. Livingston B.D., Crimi C., Grey H., Ishioka G., Chisari F.V., Fikes J.et al. The hepatitis C virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited with acute viral infection. J. Immunol. 159:1997;1383-1392.
26. Gahéry-Sédard H., Pialoux G., Charmeteau B., Sermet S., Poncelet H., Raux M.et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74:2000;1694-1703.
27. Langhans B., Braunschweiger I., Schweitzer S., Jung G., Inchauspe G., Sauerbruch T.et al. Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro. Immunology. 102:2001;460-465.
28. Thiele D.L., Lipsky P.E. Modulation of human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells. J. Immunol. 135:1985;786-793.
29. Mason P.D., Weetman A.P., Sissons J.G.P., Borysiewicz L.K. Suppressive role of NK cells in pokeweed mitogen-induced immunoglobulin synthesis: effects of depletion/enrichment of Leu11b+ cells. Immunology. 65:1988;113-118.
30. Hoffmann P, Jimenes-Diaz M, Loleit M, Tröger W, Weismüller K-H, Metzger J, et al. Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunisation. Hum Antibody Hybridomas 1990:137-44.
31. Niedbala W., Kurpisz M. In vitro sensitization for human monoclonal antibody production. Immunol. Lett. 35:1993;93-100.
32. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahresdorfer B., Giese T.et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:2002;4531-4537.
33. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 21:2003;335-376.
34. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416:2002;603-607.
35. Langhans B, Schweitzer S, Nischalke HD, Braunschweiger I, Sauerbruch T, Spengler U. Differential induction of epitope-specific immune responses by hepatitis C virus (HCV)-derived lipopeptides. JID [in press].